Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

CEL-SCI Corp (NYSE MKT LLC:CVM)

0.1139
Delayed Data
As of Dec 02
 -0.0654 / -36.48%
Today’s Change
0.10
Today|||52-Week Range
0.66
-69.22%
Year-to-Date
SECTOR
Health Technology
INDUSTRY
Biotechnology
MARKET CAP
$17.8M

Company Description

CEL-SCI Corp. is a biotechnology company, which is involved in the research and development of investigational immunotherapy products for the treatment of cancer and infectious diseases. The company's lead investigational therapy, Multikine is currently in a pivotal phase 3 clinical trial against advanced primary head and neck cancer. It is also developing its pre-clinical Ligand Epitope Antigen Presentation System technology for the potential treatment of pandemic influenza in hospitalized patients and as a potential vaccine for the treatment of rheumatoid arthritis. CEL-SCI was founded by Maximilian de Clara on March 22, 1983 and is headquartered in Vienna, VA.

Contact Information

CEL-SCI Corp.
8229 Boone Boulevard
Vienna Virginia 22182
P:(703) 506-9460
Investor Relations:

Employees

Shareholders

Other institutional5.93%
Mutual fund holders2.66%
Individual stakeholders13.51%

Top Executives

Geert R. KerstenCEO, CFO, Treasurer, Director & CAO
Patricia B. PrichepSecretary & Senior Vice President-Operations
Eyal TalorChief Scientific Officer
William JonesVice President-Quality Assurance
Daniel H. ZimmermanSenior VP-Research & Cellular Immunology